| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8231977 | International Journal of Radiation Oncology*Biology*Physics | 2010 | 7 Pages |
Abstract
Patients with ER/PR-negative or HER2-positive T1a,bN0 breast cancer had a greater risk of LRR. Therapeutic strategies, such as the use of chemotherapy and/or anti-HER2 therapies, should be considered for future clinical trials for these patients.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Jeffrey M. M.D., Ana M. M.D., Merih M.D., Aysegul M.D., Eric A. M.D., Welela M.D., Wendy A. M.D., Ph.D., Susan L. Ph.D., Kelly K. M.D., Gabriel N. M.D., Thomas A. M.D.,